Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com

Dow Jones

06/09

By George Glover

Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion.

Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65.

GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib.

The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years.

GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs.

Write to George Glover at george.glover@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 09, 2026 10:00 ET (14:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2642493129"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642493129\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642493129?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642493129","market":"nz","top_or_hot":-1,"title":"Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n</p>\n<p>\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n</p>\n<p>\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n</p>\n<p>\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n</p>\n<p>\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal -- Barrons.com\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-09 22:00</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By George Glover \n</p>\n<p>\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n</p>\n<p>\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n</p>\n<p>\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n</p>\n<p>\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n</p>\n<p>\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n</p>\n<p>\n  Write to George Glover at george.glover@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 09, 2026 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSKH","symbol_name":"GSK plc ADRhedged","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642493129","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642493129","pubTimestamp":1781013600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion.Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65.GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib.The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years.GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSKH":"GSK plc ADRhedged","BK4139":"生物科技","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","BK4007":"制药","BK4588":"碎股","NUVL":"Nuvalent, Inc.","GSK.UK":"葛兰素史克","BK4539":"次新股","BK4585":"ETF&股票定投概念"},"translate_title":"葛兰素史克(GSK)癌症药物意外交易导致Nuvalent股价上涨39%--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSKH":0.6,"GSK":1.5,"NUVL":1.5,"GSK.UK":0.6},"content_text":"By George Glover \n\n\n  Nuvalent stock was soaring Tuesday after British pharmaceutical company GSK said it had agreed to buy the cancer-drug developer for $10.6 billion. \n\n\n  Shares of Nuvalent jumped 39% to $122.90. GSK's American depositary receipts were flat at $50.65. \n\n\n  GSK is making a tender offer for Nuvalent at $124 a share in cash, a 40% premium to where Nuvalent stock traded as of Monday's closing bell. The biotech has two experimental lung-cancer drugs in late development, zidesamtinib and neladalkib. \n\n\n  The deal may rattle GSK shareholders, given it would be the company's biggest acquisition in eight years. \n\n\n  GSK swapped its oncology business for Novartis' vaccines division in a 2014 deal, but is now trying to strengthen its pipeline of cancer drugs. \n\n\n  Write to George Glover at george.glover@dowjones.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 10:00 ET (14:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}